Zhang Yingjia, Weady Peter, Duggal Rohit, Hao Weidong
Department of Exploratory Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10628 Science Center Drive, San Diego, CA 92121, USA.
Antimicrob Agents Chemother. 2008 Feb;52(2):666-74. doi: 10.1128/AAC.01133-07. Epub 2007 Nov 26.
A major obstacle in hepatitis C virus (HCV) research has been the lack of a permissive cell culture system that produces infectious viral particles. Significant breakthroughs have been achieved lately in establishing such culture systems. Yet to date, there are no reports of the applications of any of these systems in HCV drug screening. Here, we report the generation of two monocistronic, chimeric genotype 1 full-length HCV genome molecules. These molecules, C33J-Y835C-UBI and C33J-Y835C-FMDV2A, both contain the structural protein region from genotype 1 (subtype 1b, Con1) and the remaining region from the genotype 2a (JFH1) clone. Both contain the humanized Renilla luciferase reporter gene which is separated from the rest of the HCV open reading frame by two different cleavage sites. The viral RNAs replicated efficiently in transfected cells. Viral particles produced were infectious in naïve Huh7.5 cells, and the infectivity could be blocked by monoclonal antibody against a putative HCV entry cofactor, CD81. A pilot high-throughput screen of 900 unknown compounds was executed by both the genotype 2a subgenomic replicon system and the infectious system. Thirty-one compounds were identified as hits by both systems, whereas 78 compounds were identified as hits only for the infectious system, suggesting that the infectious system is capable of identifying inhibitors targeting the viral structural proteins and steps involving them in the viral life cycle. The infectious HCV system developed here provides a useful and versatile tool which should greatly facilitate the identification of HCV inhibitors currently not identified by the subgenomic replicon system.
丙型肝炎病毒(HCV)研究中的一个主要障碍是缺乏能够产生感染性病毒颗粒的允许性细胞培养系统。最近在建立此类培养系统方面取得了重大突破。然而,迄今为止,尚无关于这些系统中任何一个在HCV药物筛选中的应用报告。在此,我们报告了两种单顺反子、嵌合基因型1全长HCV基因组分子的产生。这些分子,C33J - Y835C - UBI和C33J - Y835C - FMDV2A,均包含来自基因型1(亚型1b,Con1)的结构蛋白区域和来自基因型2a(JFH1)克隆的其余区域。两者都包含人源化的海肾荧光素酶报告基因,该基因通过两个不同的切割位点与HCV开放阅读框的其余部分分开。病毒RNA在转染细胞中有效复制。产生的病毒颗粒对未感染的Huh7.5细胞具有感染性,并且其感染性可被针对假定的HCV进入辅助因子CD81的单克隆抗体阻断。通过基因型2a亚基因组复制子系统和感染性系统对900种未知化合物进行了初步高通量筛选。两个系统均鉴定出31种化合物为命中物,而仅感染性系统鉴定出78种化合物为命中物,这表明感染性系统能够鉴定靶向病毒结构蛋白及其在病毒生命周期中所涉及步骤的抑制剂。在此开发的感染性HCV系统提供了一种有用且通用的工具,应能极大地促进目前亚基因组复制子系统未鉴定出的HCV抑制剂的鉴定。